Step 1 topics → Hematology and Oncology → Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia (CML)

USMLE Step 1 trap: Confuses CML's low LAP score with the high LAP score of leukemoid reactions. CML has a characteristically LOW LAP score because the neoplastic granulocytes are functionally deficient, whereas leukemoid reactions show a HIGH LAP score.

CML is one of the most high-yield leukemias on USMLE Step 1 because it hits multiple testable domains at once: genetics, pathophysiology, lab findings, and targeted therapy. The core concept is the Philadelphia chromosome — a t(9;22) translocation producing a constitutively active BCR-ABL tyrosine kinase. The most common single-lab-value trap: both CML and a leukemoid reaction (e.g., from severe infection) can produce a WBC of 80,000+ with a full granulocytic spectrum, but only CML has a LOW LAP score — the neoplastic cells can't make alkaline phosphatase normally. The exam will give you a sky-high WBC and expect you to use that single value to distinguish CML from a reactive process.

What makes CML tricky is that it sits at the intersection of several easily confused concepts. Students frequently mix up the LAP score with leukemoid reactions, misidentify what happens during blast crisis, and conflate imatinib's mechanism with other cancer therapies. USMLE Step 1 loves to test these distinctions in vignette form — for example, presenting two patients with high WBCs and asking you to differentiate CML from a leukemoid reaction based on a single lab value like the LAP score. Getting this wrong usually means having a flawed mental model rather than just forgetting a fact.

The three big angles the exam hits are: (1) the cytogenetics and how BCR-ABL drives disease, (2) the clinical presentation across the three phases (chronic, accelerated, blast crisis) with associated CBC and lab patterns, and (3) the mechanism and impact of TKI therapy. Understanding why each piece is the way it is — not just memorizing it — is what separates students who get these questions right from those who get tricked.

From real student decks
92%have cards covering this topic
86%have mature cards
2.0median lapses in 14 days

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: The leukocyte alkaline phosphatase (LAP) score is elevated in CML just as it is in leukemoid reactions.
Right: CML has a characteristically LOW LAP score because the neoplastic granulocytes are functionally deficient, whereas leukemoid reactions show a HIGH LAP score.
This is one of the classic Step 1 traps. In a leukemoid reaction, the granulocytes are normal functioning cells that produce plenty of alkaline phosphatase — so LAP is HIGH. In CML, the proliferating granulocytes are neoplastic and functionally deficient, so they fail to produce adequate alkaline phosphatase — LAP is LOW. Use this as a diagnostic anchor: when the exam gives you a sky-high WBC and asks how to distinguish CML from infection-driven leukocytosis, a low LAP score points directly to CML.
Common mistake
Wrong: Blast crisis in CML always produces myeloid blasts.
Right: Blast crisis in CML can be myeloid (~70%) or lymphoid (~30%), and lymphoid blast crisis paradoxically responds better to treatment.
It's tempting to think blast crisis is just an extreme version of myeloid disease since CML is a myeloid neoplasm, but about 30% of blast crises are lymphoid in origin. This happens because the BCR-ABL mutation occurs in a pluripotent stem cell, so the clone retains the potential to go down a lymphoid path. The clinically important corollary is that lymphoid blast crisis responds better to treatment — including TKIs plus ALL-type induction regimens — so identifying the blast lineage by immunophenotyping actually changes management.
Common mistake
Wrong: Imatinib works by inducing differentiation of CML blasts similar to ATRA in APL.
Right: Imatinib competitively inhibits the BCR-ABL tyrosine kinase ATP-binding site, blocking constitutive proliferative signaling rather than inducing differentiation.
ATRA works in APL by binding the PML-RARα fusion protein and releasing its block on differentiation — it essentially forces the blasts to grow up. Imatinib does something completely different: it fits into the ATP-binding pocket of BCR-ABL and blocks the kinase from phosphorylating its downstream targets, cutting off the proliferative signal entirely. There is no differentiation induction involved. Confusing these two mechanisms is particularly dangerous because it reflects a broader confusion between the two most elegant examples of targeted oncology therapy on USMLE Step 1.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. You need to know the Philadelphia chromosome — t(9;22) — creates the BCR-ABL fusion gene, and that BCR-ABL is a constitutively active tyrosine kinase that drives CML by continuously signaling cells to proliferate without the normal growth factor triggers.
  2. You need to recognize the clinical and lab picture of CML: markedly elevated WBC with the full granulocyte spectrum on smear, thrombocytosis, massive splenomegaly, and a characteristically LOW leukocyte alkaline phosphatase (LAP) score that distinguishes it from benign leukemoid reactions.
  3. You need to understand the three disease phases (chronic, accelerated, blast crisis), what defines blast crisis (≥20% blasts), that it can be myeloid or lymphoid, and why the lymphoid variant responds better to treatment.
  4. You need to know that imatinib (and other TKIs) work by competitively blocking the ATP-binding site of BCR-ABL tyrosine kinase, and that TKI therapy dramatically changed CML's natural history by converting it from a uniformly fatal disease into a manageable chronic condition.

Can you avoid these mistakes?

A 52-year-old man presents with fatigue and early satiety. CBC shows WBC 120,000/µL with the full spectrum of granulocytes, platelets 650,000/µL, and spleen palpable 8 cm below the costal margin. His LAP score comes back low. What is the diagnosis, and what single cytogenetic finding would you expect to confirm it?
A patient with known CML is found to have 25% blasts in the bone marrow. Flow cytometry shows the blasts are TdT-positive and CD19-positive. What phase of CML is this, what lineage are the blasts, and how does this lineage finding affect prognosis compared to the alternative?
A classmate says imatinib works like ATRA — it forces the CML cells to finally differentiate instead of proliferating. How would you correct this explanation? What is imatinib actually targeting, and what is the molecular consequence of that inhibition?
You are given two patients: Patient A has WBC 80,000/µL in the setting of severe pneumonia; Patient B has WBC 85,000/µL with splenomegaly and no infection. Both have predominantly neutrophilic smears. What single lab test would most efficiently distinguish these two, and what result would you expect in each patient?

Related topics

Leukemia vs Lymphoma Framework Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →